Last $57.33 USD
Change Today +0.08 / 0.14%
Volume 5.2M
MYL On Other Exchanges
As of 5:20 PM 02/27/15 All times are local (Market data is delayed by at least 15 minutes).

mylan inc (MYL) Snapshot

Previous Close
Day High
Day Low
52 Week High
11/28/14 - $59.60
52 Week Low
04/15/14 - $44.74
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for MYLAN INC (MYL)

mylan inc (MYL) Details

Mylan Inc., a pharmaceutical company, develops, licenses, manufactures, markets, and distributes generic, branded generic, and specialty pharmaceuticals worldwide. It operates in two segments, Generics and Specialty. The Generics segment primarily provides generic or branded generic pharmaceutical products in tablet, capsule, injectable, or transdermal patch form, as well as active pharmaceutical ingredients (APIs). This segment is also involved in developing APIs with non-infringing processes to partner with manufacturers; and the manufacture and sale of injectable products in the therapeutic areas of antineoplastics, anti-infectives, anesthesia/pain management, and cardiovascular. In addition, it produces finished dosage form (FDF) products for the antiretroviral (ARV) market and non-ARV FDF products that are marketed to third parties. This segment serves proprietary and ethical pharmaceutical wholesalers and distributors, group purchasing organizations, drug store chains, independent pharmacies, drug manufacturers, institutions, and public and governmental agencies. The Specialty segment manufactures and sells branded specialty injectable and nebulized products comprising EpiPen Auto-Injector for the treatment of severe allergic reactions; and Perforomist Inhalation Solution, a formoterol fumarate inhalation solution for the maintenance treatment of bronchoconstriction in chronic obstructive pulmonary disorder patients. It also offers ULTIVA, an analgesic agent used during the induction and maintenance of general anesthesia. This segment serves pharmaceutical wholesalers and distributors, pharmacies, and healthcare institutions. Mylan Inc. has a strategic collaboration with Pfizer Japan Inc. to develop, manufacture, distribute and market generic drugs in Japan. The company was formerly known as Mylan Laboratories Inc. and changed its name to Mylan Inc. in October 2007. Mylan Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.

20,000 Employees
Last Reported Date: 02/27/14
Founded in 1961

mylan inc (MYL) Top Compensated Officers

Chief Executive Officer, Director and Member ...
Total Annual Compensation: $1.1M
President, Director and Member of Science & T...
Total Annual Compensation: $840.4K
Executive Chairman and Chairman of Executive ...
Total Annual Compensation: $1.4M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $650.0K
Compensation as of Fiscal Year 2013.

mylan inc (MYL) Key Developments

Sun Pharmaceutical Planning To Sell Assets; Cipla Among Possible Buyers

Sun Pharmaceutical Industries Limited (BSE:524715) may sell some assets. The company is selling seven brands as per the order of the Competition Commission of India (CCI). According to the news report, firms like Cipla Limited (BSE:500087), Natco Pharma Limited (BSE:524816), Mylan, Inc. (NasdaqGS:MYL), Intas Pharmaceuticals Ltd. and Emcure Pharmaceuticals Limited are interested in acquiring select brands of Sun Pharma. The deal is likely to be completed in a month. According to the All India Organization of Chemists and Druggists Association, the total value of the drug brands proposed for sale is about INR 1.37 billion.

Bayer Healthcare LLc, Bayer Healthcare Pharmaceuticals Inc., and Onyx Pharmaceuticals Inc., Sues Mylan Inc. and Mylan Pharmaceuticals

Mylan Inc. confirmed that it and its subsidiary Mylan Pharmaceuticals have been sued by Bayer Healthcare LLC, Bayer Healthcare Pharmaceuticals Inc., and Onyx Pharmaceuticals Inc., in connection with the filing of an Abbreviated New Drug Application with the U.S. Food and Drug Administration for Sorafenib Tablets, 200 mg. The product is the generic version of Nexavar, which is indicated for the treatment of certain types of cancers including unresectable hepatocellular carcinoma and advanced renal cell carcinoma. Mylan believes that it is the first company to have filed a substantially complete ANDA containing a Paragraph IV certification for the product and expects to be eligible for 180 days of marketing exclusivity upon receiving final FDA approval. The plaintiffs have filed suit against the Mylan companies in the United States District Court in the District of Delaware.

Theravance Biopharma, Mylan to Develop and Commercialize New LAMA Compound to Treat COPD

Theravance Biopharma and Mylan are set to jointly develop and commercialize a new investigational once-daily nebulized long-acting muscarinic antagonist (LAMA), TD-4208, to treat chronic obstructive pulmonary disease (COPD) and other respiratory diseases. In multiple Phase II trials, TD-4208 has shown positive top-line results in COPD patients, and recently the FDA had agreed to the design of the Phase III registrational program that is scheduled to begin in 2015. According to the firms, TD-4208 has the potential to be a best-in-class once-daily single-agent nebulized product for COPD patients who require, or prefer, nebulized therapy. As part of the deal, Theravance will lead the US registrational development program, while Mylan will be responsible for reimbursement of Theravance's costs for that program up until the approval of the first new drug application (NDA), after which costs will be shared. Additionally, Mylan will be responsible for commercial manufacturing of the product. In the US, Mylan will lead commercialization and Theravance will retain the right to co-promote the product under a profit-sharing arrangement. Outside the US (excluding China), Mylan will be responsible for the product's development and commercialization and pay Theravance a royalty on net sales. Theravance retains worldwide rights to TD-4208 delivered through other dosage forms, such as a metered dose inhaler or dry powder inhaler (MDI/DPI). Apart from funding the US registrational development program, Mylan will pay Theravance an initial payment of $15 million in cash and has agreed to make a $30 million equity investment by purchasing newly issued Ordinary Shares at a price of $18.92 per share. Under the deal, Theravance is eligible to receive potential development and sales milestone payments totaling $220 million in the aggregate, with $175 million associated with TD-4208 monotherapy and $45 million for future potential combination products.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MYL:US $57.33 USD +0.08

MYL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Becton Dickinson and Co $146.72 USD -1.82
Hospira Inc $87.54 USD 0.00
Perrigo Co PLC $154.47 USD -0.78
UCB SA €68.35 EUR -1.26
WW Grainger Inc $236.91 USD -3.47
View Industry Companies

Industry Analysis


Industry Average

Valuation MYL Industry Range
Price/Earnings 24.7x
Price/Sales 2.9x
Price/Book 6.3x
Price/Cash Flow 23.3x
TEV/Sales 1.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MYLAN INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at